Drug Type Small molecule drug |
Synonyms ETC-1002/ezetimibe, Ezetimibe/ETC-1002, Ezetimibe/bempedoic acid + [3] |
Target |
Mechanism ACL inhibitors(ATP-citrate synthase inhibitors), NPC1L1 inhibitors(Niemann-Pick C1-like protein 1 inhibitors), Cholesterol absorption inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (26 Feb 2020), |
Regulation- |
Molecular FormulaC24H21F2NO3 |
InChIKeyOLNTVTPDXPETLC-XPWALMASSA-N |
CAS Registry163222-33-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cardiovascular Diseases | US | 22 Mar 2024 | |
Myocardial Infarction | US | 22 Mar 2024 | |
Primary Hyperlipidemia | US | 22 Mar 2024 | |
Dyslipidemias | EU | 27 Mar 2020 | |
Dyslipidemias | NO | 27 Mar 2020 | |
Dyslipidemias | LI | 27 Mar 2020 | |
Dyslipidemias | IS | 27 Mar 2020 | |
Primary hypercholesterolemia | LI | 27 Mar 2020 | |
Primary hypercholesterolemia | EU | 27 Mar 2020 | |
Primary hypercholesterolemia | IS | 27 Mar 2020 | |
Primary hypercholesterolemia | NO | 27 Mar 2020 | |
Atherosclerosis | US | 26 Feb 2020 | |
Heterozygous familial hypercholesterolemia | US | 26 Feb 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiovascular Diseases | NDA/BLA | EU | 21 Mar 2024 |